Arbutus Biopharma CorporationABUSNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-26.68%
↓ 593% below average
Average (9y)
5.41%
Historical baseline
Range
High:33.09%
Low:-26.68%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | -26.68% |
| 2023 | -12.69% |
| 2022 | 28.86% |
| 2021 | 32.76% |
| 2020 | -14.35% |
| 2019 | -0.52% |
| 2018 | -7.66% |
| 2017 | 2.28% |
| 2016 | 19.02% |
| 2015 | 33.09% |